Exor N.V. Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001589122

What is a 13F filing? Who files one and when · What 13F filings can't tell you

LargeFocusedIndustrials TiltHigh Turnover how tags are computed

Q2 2026 · 4 positions · Total reported value $20.77B · Top-10 concentration 100.0% · Updated 2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

Turnover: 42.9% · 3 new · 0 cut · 0 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

In its Q2 2026 13F filing, Exor N.V. disclosed 4 equity positions with a combined reported value of $20.77B. The filing implies a focused portfolio: its ten largest positions account for 100.0% of reported value. HoldingsHub classifies the profile as Large / Focused / Industrials Tilt / High Turnover.

The largest disclosed positions as of Q2 2026 were RACE ($14.06B), CNH ($4.12B), STLA ($2.58B). By sector, the heaviest allocations are Industrials 100.0%, Health Care 0.0%.

Versus the prior quarter, Exor N.V. opened 3 new positions, trimmed 0 and fully exited 0, a turnover rate of 42.9% of positions. The portfolio's overlap with the prior quarter was 100% of names.

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

Insider Transactions (Form 4)

Latest Exor N.V. buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Exor N.V. is an SEC-registered 13F filer. As of Q2 2026 it reported 3 US equity positions with a combined value of $5.46B. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Portfolio Structure

  • 3 positions · $5.46B reported value (Q2 2026)
  • Top 10 holdings = 100.0% of reported value
  • Largest position: PHG (KONINKLIJKE PHILIPS N V) at 92.6%
  • Average position size: $1.82B

Sector Tilt

  • Health Care 92.6%
  • Information Technology 7.4%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q2 2026: 1 added
  • 2 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall Direction and Market View: Exor N.V. appears to maintain a conservative stance in their Q2 2026 rebalancing, with a focus on holding onto existing positions rather than making significant additions or reductions. This suggests a preference for stability and possibly a defensive posture amidst market uncertainty or volatility. 2. Key Moves: - Addition: Philips (PHG) was added or increased to 92.64% of the portfolio, representing a 1.9% increase in shares from the previous quarter. - No Change: VIA (VIA) and Clarivate (CLVT) remained constant at 4.69% and 2.66% respectively, with no change in shares held. - No Reductions: There were no reductions in any holdings this quarter. 3. Portfolio Structure: - Passive/Active: The portfolio seems to lean more towards passive management, as indicated by the "Hold" action on all positions and no significant changes in weightings. - Sector Bias: The portfolio has a strong bias towards the Health Care sector, with Philips being the largest holding. - Risk Appetite: The conservative rebalancing suggests a lower risk appetite, with a preference for stable, mature companies. 4. Per-Holding One-Liner: - PHG (Philips N.V.): Major global health technology company; 'unverified' - VIA (VIA Technologies, Inc.): Semiconductor and computing products company; 'unverified' - CLVT (Clarivate PLC): Provider of analytics and information to professionals in the science, academic and healthcare markets; 'unverified' 5. One-Sentence Style Summary: Exor N.V. maintained a stable, defensive portfolio in Q2 2026, focusing on a high concentration in the Health Care sector and holding onto existing investments with minimal changes.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice.

Sector Allocation

Industrials 100.0%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 37.77M $14.06B 67.70%
67.70%
Hold
2 366.93M $4.12B 19.84%
19.84%
Hold
3 449.41M $2.58B 12.42%
12.42%
Hold
4 4.22M $7.17M 0.04%
0.04%
Hold

FAQ

What did Exor N.V. buy in 2026-Q2?

In its 2026-Q2 13F filing, Exor N.V. reported 4 equity positions worth $20.77B in aggregate; its largest disclosed positions were RACE ($14.06B), CNH ($4.12B), STLA ($2.58B).

How large is Exor N.V.'s portfolio?

Exor N.V. reported $20.77B of long equity holdings across 4 positions as of 2026-Q2. Top-10 holdings account for 100.0% of reported value.

What is Exor N.V.'s investment style?

HoldingsHub classifies the portfolio as Large / Focused / Industrials Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/exor/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →